NGMedical GmbH Announces First Case of Its BEE PLIF in the USA

NGMedical, a German medical device manufacturer exclusively focused on creating innovative technologies for spinal applications announces the first USA implantation of its purely additively manufactured titanium BEE® PLIF.

The case was performed on February 18th, 2022 by Jonathan A. Tuttle, MD at University Hospital in Augusta, GA.

“The BEE® PLIF implant system represents a refinement of details that matter.  The instruments are elegant and intuitive, and the implant is refined in structure and anatomical design.  I’m pleased to incorporate BEE® PLIF into my armamentarium of surgical solutions for my patients,” said Dr. Tuttle.

Mitch White, President of NGMedical, Inc. added, “I’m excited and honored Dr. Tuttle was the first US surgeon to implant BEE® PLIF, but I’m not surprised.  Dr. Tuttle had a discerning appreciation for the BEE® PLIF’s evolutionary design, and was anxious for BEE® as a surgical option. This promises to be a year of rapid growth as we introduce the inimitable BEE® platform of interbody implants across the country.”

“This successful market launch in the USA is an important step for NGMedical. The first operation with the BEE® PLIF cage in this important market is a great milestone in our international commercialization. We look forward to expanding our portfolio and footprint in the USA.” says Peter Weiland, CEO of NGMedical.

NG Medical notes the BEE® PLIF cage is another significant innovation from the team who invented the first line of additively manufactured interbody devices. The purposefully designed honeycomb endplate design reduces the risk of subsidence, while allowing fusion. The honeycomb structure allows for bony ingrowth while offering a very large graft space. Smooth lateral surfaces facilitate insert and rotate technique. BEE® PLIF is offered in a wide range of sizes up to 18° lordosis.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.